Daebongls.Co.,Ltd. reported earnings results for the third quarter and nine months ended September 30, 2025. For the third quarter, the company reported sales was KRW 24,834.56 million compared to KRW 24,232.34 million a year ago. Net income was KRW 970.86 million compared to KRW 5,970 million a year ago. Basic earnings per share from continuing operations was KRW 89 compared to KRW 545 a year ago. Diluted earnings per share from continuing operations was KRW 110. Basic earnings per share was KRW 89 compared to KRW 545 a year ago. Diluted earnings per share was KRW 110.
For the nine months, sales was KRW 0.00001 million compared to KRW 0.00001 million a year ago. Net income was KRW 10,843 million compared to KRW 8,199.41 million a year ago. Basic earnings per share from continuing operations was KRW 990 compared to KRW 749 a year ago. Diluted earnings per share from continuing operations was KRW 891. Basic earnings per share was KRW 990 compared to KRW 749 a year ago. Diluted earnings per share was KRW 891.
DaebongLS Co Ltd is a Korea-based company primarily engaged in the manufacture of pharmaceutical and cosmetic ingredients. The Company operates its business through two segments. The Pharmaceutical Active Ingredient Business segment provides active pharmaceutical ingredients for respiratory treatments, hypertension treatments, and digestive system treatments. The Cosmetic Material Business segment manufactures and sells natural and functional cosmetic ingredients. In addition, the Company provides testing services for materials used on the skin and engages in real estate leasing business. The Company sells its products in domestic and overseas markets.
